Navigation Links
NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont
Date:12/10/2009

The National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis.

Salt Lake City, UT (PRWEB) December 10, 2009 -- The National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. Aciont’s Visulex® treatment entails a proprietary combination of a topical formulation and a scleral lens-shaped eye application device that administers drug to eye within 5-10 minutes. Aciont completed work under the proof of concept phase of the grant with the support of research faculty at the University of Utah’s departments of pharmaceutics and pharmaceutical chemistry and the John A. Moran Eye Center.

The PI of the project is William I. Higuchi, Aciont’s founder and chief scientific officer. Important Moran Center advisors to the project are Nick Mamalis—a world renowned expert on intraocular lenses, postoperative inflammation and ocular pathology; and Albert T. Vitale—a vitreoretinal surgeon and world renowned authority in the diagnosis and treatment of uveitis and related ocular inflammation diseases.

“I think that this product has promise for the treatment of anterior, posterior and panuveitis patients,” said Dr. Vitale. Uveitis refers to inflammation of the middle layer of the eye wall called the uvea. However, the term uveitis often refers to inflammation of any of the internal parts of the eye and it can affect the anterior, middle area and posterior sections of the eye globe. Uveitis is the third leading cause of blindness in the United States. Some estimate the number of uveitis patients in North America to be as high as 500,000. Vitale added, “The real utility will be the delivery of medication to the back of the eye for intermediate and posterior uveitis particularly that are complicated by macular edema.”

Furthermore, Vitale concluded, “Certainly a transscleral delivery of drug would be preferable to intravitreal injection. This in my opinion has definitive potential.” The NEI peer review council, which recommended the funding of Aciont’s project, generally agrees with Vitale in principal. The council said that “the development of a non-invasive ocular drug delivery system allowing for a simple and quick application of medications for the treatment of uveitis” is “significant since it would allow treatment of this painful and potentially blinding disease in the doctor’s office by a nurse or paraprofessional.” The project described is supported by Award Number R44EY014772 from the National Eye Institute. The content of the grant is solely the responsibility of the authors and does not necessarily represent the official views of the National Eye Institute or the National Institutes of Health.

Dr. Balbir Brar, who had a significant role in the development of the grant application stated, “Acquiring this NIH grant is a great achievement and a major milestone for the Aciont team. Obtaining the NIH grant in a highly competitive environment essentially is an endorsement by peers in our field of research and industry.” Bal Brar, D.V.M., Ph.D, is well known for his success as a drug/device developer; he is a former Vice President at Allergan®, Inc. where he played a major role in the development of a number of high selling dermal and ophthalmic drugs such as Alphagan®, Lumigan® for glaucoma, Restasis® for dry eye and a number of other drugs including Botox®.

According to NIH’s website (http://report.nih.gov/recovery/arragrants.cfm), Aciont is the only recipient of an SBIR award in the State of Utah funded by the NIH ARRA program in FY 2009. Also, the FY 2009 award to Aciont represents the largest funding amount to a Utah organization for any ARRA NIH project pertaining to the development of a pharmaceutical or therapeutic treatment of a disease. Aciont is eligible for applying for an extension to this project under NIH’s competing renewal award program.

Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah. For more information, visit the company’s website at aciont.com.

Source: Aciont Inc.

Contact:
John Higuchi, CEO
Aciont Inc.
(801) 359-3461
admin (at) aciont (dot) com

###

Read the full story at http://www.prweb.com/releases/2009/12/prweb3313064.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards
2. Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award
3. Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards
4. US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine
5. Professional Pricing Society Announces Educational Partnership with Vendavo -- "PPS Accepting Vendavo Pricing Knowledge Series Awards to Certified Pricing Professional Program"
6. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
7. Frost & Sullivans 2009 Excellence in Healthcare Awards Banquet Honours Industrys Top Performers
8. Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
9. Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards
10. Southern California Venture Network to Recognize Local Companies At 2009 Emerging Growth Awards
11. Leading Biotechnology Company Awards Phase III Cardiac Safety Study to iCardiac
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):